Core Viewpoint - Sarissa Capital Management has established a new position in Biohaven Ltd., acquiring 513,184 shares valued at $5.79 million, indicating a strategic investment in the clinical-stage biotechnology company focused on neurological and immunoscience disorders [1][2]. Company Overview - Biohaven Ltd. is a clinical-stage biotechnology company that develops innovative therapies for neurological and immunoscience disorders, aiming to address unmet medical needs through proprietary research [5]. - As of the latest data, Biohaven's stock price is $8.90, with a market capitalization of $1.3 billion and a net income of -$738.8 million [4]. Financial Position - Biohaven ended 2025 with approximately $322 million in cash and raised an additional $178.9 million post-year-end, providing financial stability to navigate key clinical readouts [10]. - The company has seen a significant decline in its stock price, down 70% over the past year, contrasting with the S&P 500's increase of about 15% during the same period [7]. Investment Implications - The new position in Biohaven represents 2.6% of Sarissa Capital's reportable U.S. equity AUM, aligning with the fund's strategy of investing in clinical-stage biotech companies [7]. - Biohaven's management is focusing on a smaller set of late-stage programs, including a degrader platform and a Phase 2 obesity candidate, with data expected later in 2026, which could serve as a potential catalyst for the company [9][10]. Market Context - The company is currently viewed as a "reset story" following the FDA rejection of its drug, troriluzole, and disappointing trial updates, but the underlying strategy remains intact [9]. - Biohaven's business model is centered on research and development, with future revenue anticipated from licensing and commercialization of proprietary treatments targeting healthcare providers and patients affected by neurological and immune-related conditions [8].

Core Insights - 5AM Venture Management, LLC has completely liquidated its position in Viking Therapeutics, resulting in a net position change of approximately $5.02 million [2][3][7] Company Overview - Viking Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for metabolic and endocrine diseases [9] - The company has a pipeline of orally available drug candidates aimed at addressing significant unmet medical needs, including non-alcoholic steatohepatitis and rare genetic disorders [9] Financial Performance - As of November 18, 2025, shares of Viking Therapeutics were priced at $38.00, reflecting a year-to-date performance decline of 5.6% [4][5] - The company's stock has underperformed the S&P 500 by 18.7 percentage points during the same period [4] Investment Position - Following the sale, Viking Therapeutics now represents 0% of 5AM Venture Management's reportable assets under management (AUM) [4][7] - Previously, Viking Therapeutics accounted for approximately 1.9% of the fund's AUM [3][7] Market Context - The exit from Viking Therapeutics by 5AM Venture Management is viewed as a rebalancing strategy rather than a lack of confidence in the company's scientific endeavors [10] - Viking Therapeutics operates in a market characterized by significant patient needs, but the path to commercialization is often lengthy and fraught with challenges [11][12]